Xilio Therapeutics IncXLO
Price$9.05Intrinsic value$9.839% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $9.83median of 2 methodsbased on filings through 31 Dec 2025
Market Price $9.05Price as of 30 Sep 2026
Margin of Safety +8.6%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 9.6%/yr (balance of the path).8.7% per year
Years 6–10: glide to demonstrated growth own history 31.7%, capped at 20%
Per-year rates
Yr 69.4%Yr 79.3%Yr 89.1%Yr 98.9%Yr 108.7%
9.6% → 8.7%
Years 11–20: glide to long-run rate
Per-year rates
Yr 118.1%Yr 127.6%Yr 137.0%Yr 146.4%Yr 155.8%Yr 165.3%Yr 174.7%Yr 184.1%Yr 193.6%Yr 203.0%
8.7% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)31.7%
Discount rate (cost of equity) 9.4%
Volatility vs market (adjusted beta)1.00

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetXilio Therapeutics IncXLOHealth Care
Valuation
P/E—
P/S1.4×
P/B1.5×
EV / Revenue-2.2×
EV / EBITDA2.4×
Profitability
Gross margin96.5%
Operating margin-95.9%
Net margin-80.1%
FCF margin-12.6%
Returns
ROE-99.3%
ROA-22.7%
ROIC—
Growth
Revenue growth (YoY)590.4%
5-yr fwd EPS growth8.7%
Financial strength
Debt / Equity0.20×
Current ratio—
Altman Z-Score—
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.